• レポートコード:QYR2104Z4249 • 出版社/出版日:QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態:英文、PDF、90ページ • 納品方法:Eメール(納期:3日) • 産業分類:医療 |
Single User | ¥553,800 (USD3,900) | ▷ お問い合わせ |
Multi User/Five User | ¥830,700 (USD5,850) | ▷ お問い合わせ |
Enterprise License(同一法人内共有可) | ¥1,107,600 (USD7,800) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査資料では、オリゴヌクレオチド治療薬のグローバル市場(2016年~2027年)について調べ、市場動向、主要企業の市場シェア、種類別市場規模(アンチセンスオリゴヌクレオチド、アプタマー、その他)、用途別市場規模(神経筋疾患、ATTR、肝VOD、その他)、主要地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、関連企業情報などを掲載しています。 ・市場概要 ・オリゴヌクレオチド治療薬の市場動向 ・企業の競争状況、市場シェア ・オリゴヌクレオチド治療薬の種類別市場規模(アンチセンスオリゴヌクレオチド、アプタマー、その他) ・オリゴヌクレオチド治療薬の用途別市場規模(神経筋疾患、ATTR、肝VOD、その他) ・オリゴヌクレオチド治療薬の北米市場規模2016-2027(アメリカ、カナダ) ・オリゴヌクレオチド治療薬のヨーロッパ市場規模2016-2027(ドイツ、フランス、イギリス等) ・オリゴヌクレオチド治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等) ・オリゴヌクレオチド治療薬の中南米市場規模2016-2027(メキシコ、ブラジル) ・オリゴヌクレオチド治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等) ・主要企業情報(Biogen、Sarepta Therapeutics、Jazz Pharmaceuticals、Bausch & Lomb、Alnylam Pharmaceuticals、Dynavax Technologies、Kastle therapeutics、Akcea Therapeutics) ・結論 |
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Biogen is the industry’s biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Market Analysis and Insights: Global Oligonucleotide Therapeutics Market
The global Oligonucleotide Therapeutics market size is projected to reach US$ 7961.1 million by 2026, from US$ 2670.1 million in 2019, at a CAGR of 16.7% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oligonucleotide Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oligonucleotide Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oligonucleotide Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oligonucleotide Therapeutics market.
Global Oligonucleotide Therapeutics Scope and Market Size
Oligonucleotide Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oligonucleotide Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.
Segment by Application
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Other
1.3 Market by Application
1.3.1 Global Oligonucleotide Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Neuromuscular Diseases
1.3.3 ATTR
1.3.4 Hepatic VOD
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Therapeutics Market Perspective (2016-2027)
2.2 Oligonucleotide Therapeutics Growth Trends by Regions
2.2.1 Oligonucleotide Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oligonucleotide Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Oligonucleotide Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Oligonucleotide Therapeutics Industry Dynamic
2.3.1 Oligonucleotide Therapeutics Market Trends
2.3.2 Oligonucleotide Therapeutics Market Drivers
2.3.3 Oligonucleotide Therapeutics Market Challenges
2.3.4 Oligonucleotide Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Therapeutics Players by Revenue
3.1.1 Global Top Oligonucleotide Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oligonucleotide Therapeutics Revenue
3.4 Global Oligonucleotide Therapeutics Market Concentration Ratio
3.4.1 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Therapeutics Revenue in 2020
3.5 Oligonucleotide Therapeutics Key Players Head office and Area Served
3.6 Key Players Oligonucleotide Therapeutics Product Solution and Service
3.7 Date of Enter into Oligonucleotide Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide Therapeutics Breakdown Data by Type
4.1 Global Oligonucleotide Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2022-2027)
5 Oligonucleotide Therapeutics Breakdown Data by Application
5.1 Global Oligonucleotide Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Oligonucleotide Therapeutics Market Size (2016-2027)
6.2 North America Oligonucleotide Therapeutics Market Size by Type
6.2.1 North America Oligonucleotide Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Oligonucleotide Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Oligonucleotide Therapeutics Market Size by Type (2016-2027)
6.3 North America Oligonucleotide Therapeutics Market Size by Application
6.3.1 North America Oligonucleotide Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Oligonucleotide Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Oligonucleotide Therapeutics Market Size by Application (2016-2027)
6.4 North America Oligonucleotide Therapeutics Market Size by Country
6.4.1 North America Oligonucleotide Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Oligonucleotide Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Oligonucleotide Therapeutics Market Size (2016-2027)
7.2 Europe Oligonucleotide Therapeutics Market Size by Type
7.2.1 Europe Oligonucleotide Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Oligonucleotide Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Oligonucleotide Therapeutics Market Size by Type (2016-2027)
7.3 Europe Oligonucleotide Therapeutics Market Size by Application
7.3.1 Europe Oligonucleotide Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Oligonucleotide Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Oligonucleotide Therapeutics Market Size by Application (2016-2027)
7.4 Europe Oligonucleotide Therapeutics Market Size by Country
7.4.1 Europe Oligonucleotide Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Oligonucleotide Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Oligonucleotide Therapeutics Market Size by Type
8.2.1 Asia-Pacific Oligonucleotide Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oligonucleotide Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Application
8.3.1 Asia-Pacific Oligonucleotide Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Oligonucleotide Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region
8.4.1 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Oligonucleotide Therapeutics Market Size (2016-2027)
9.2 Latin America Oligonucleotide Therapeutics Market Size by Type
9.2.1 Latin America Oligonucleotide Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Oligonucleotide Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Oligonucleotide Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Oligonucleotide Therapeutics Market Size by Application
9.3.1 Latin America Oligonucleotide Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Oligonucleotide Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Oligonucleotide Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Oligonucleotide Therapeutics Market Size by Country
9.4.1 Latin America Oligonucleotide Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Oligonucleotide Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Oligonucleotide Therapeutics Market Size by Type
10.2.1 Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Application
10.3.1 Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country
10.4.1 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Oligonucleotide Therapeutics Introduction
11.1.4 Biogen Revenue in Oligonucleotide Therapeutics Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Introduction
11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2016-2021)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Details
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2016-2021)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 Bausch & Lomb
11.4.1 Bausch & Lomb Company Details
11.4.2 Bausch & Lomb Business Overview
11.4.3 Bausch & Lomb Oligonucleotide Therapeutics Introduction
11.4.4 Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2016-2021)
11.4.5 Bausch & Lomb Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2016-2021)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Dynavax Technologies
11.6.1 Dynavax Technologies Company Details
11.6.2 Dynavax Technologies Business Overview
11.6.3 Dynavax Technologies Oligonucleotide Therapeutics Introduction
11.6.4 Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2016-2021)
11.6.5 Dynavax Technologies Recent Development
11.7 Kastle therapeutics
11.7.1 Kastle therapeutics Company Details
11.7.2 Kastle therapeutics Business Overview
11.7.3 Kastle therapeutics Oligonucleotide Therapeutics Introduction
11.7.4 Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2016-2021)
11.7.5 Kastle therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Details
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Introduction
11.8.4 Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2016-2021)
11.8.5 Akcea Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Antisense Oligonucleotide
Table 3. Key Players of Aptamer
Table 4. Key Players of Other
Table 5. Global Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Oligonucleotide Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Oligonucleotide Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Oligonucleotide Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Oligonucleotide Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Oligonucleotide Therapeutics Market Share by Regions (2022-2027)
Table 11. Oligonucleotide Therapeutics Market Trends
Table 12. Oligonucleotide Therapeutics Market Drivers
Table 13. Oligonucleotide Therapeutics Market Challenges
Table 14. Oligonucleotide Therapeutics Market Restraints
Table 15. Global Oligonucleotide Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Oligonucleotide Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oligonucleotide Therapeutics as of 2020)
Table 18. Ranking of Global Top Oligonucleotide Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Oligonucleotide Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oligonucleotide Therapeutics Product Solution and Service
Table 22. Date of Enter into Oligonucleotide Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oligonucleotide Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Oligonucleotide Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Oligonucleotide Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Oligonucleotide Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Oligonucleotide Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Oligonucleotide Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Oligonucleotide Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Oligonucleotide Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Oligonucleotide Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Oligonucleotide Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Oligonucleotide Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Oligonucleotide Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Oligonucleotide Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Oligonucleotide Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Oligonucleotide Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Oligonucleotide Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Oligonucleotide Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Oligonucleotide Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Oligonucleotide Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Oligonucleotide Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Oligonucleotide Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Oligonucleotide Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Oligonucleotide Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Oligonucleotide Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Oligonucleotide Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Oligonucleotide Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Biogen Company Details
Table 63. Biogen Business Overview
Table 64. Biogen Oligonucleotide Therapeutics Product
Table 65. Biogen Revenue in Oligonucleotide Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Biogen Recent Development
Table 67. Sarepta Therapeutics Company Details
Table 68. Sarepta Therapeutics Business Overview
Table 69. Sarepta Therapeutics Oligonucleotide Therapeutics Product
Table 70. Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Sarepta Therapeutics Recent Development
Table 72. Jazz Pharmaceuticals Company Details
Table 73. Jazz Pharmaceuticals Business Overview
Table 74. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product
Table 75. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Jazz Pharmaceuticals Recent Development
Table 77. Bausch & Lomb Company Details
Table 78. Bausch & Lomb Business Overview
Table 79. Bausch & Lomb Oligonucleotide Therapeutics Product
Table 80. Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Bausch & Lomb Recent Development
Table 82. Alnylam Pharmaceuticals Company Details
Table 83. Alnylam Pharmaceuticals Business Overview
Table 84. Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product
Table 85. Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Alnylam Pharmaceuticals Recent Development
Table 87. Dynavax Technologies Company Details
Table 88. Dynavax Technologies Business Overview
Table 89. Dynavax Technologies Oligonucleotide Therapeutics Product
Table 90. Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Dynavax Technologies Recent Development
Table 92. Kastle therapeutics Company Details
Table 93. Kastle therapeutics Business Overview
Table 94. Kastle therapeutics Oligonucleotide Therapeutics Product
Table 95. Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Kastle therapeutics Recent Development
Table 97. Akcea Therapeutics Company Details
Table 98. Akcea Therapeutics Business Overview
Table 99. Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Akcea Therapeutics Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oligonucleotide Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Antisense Oligonucleotide Features
Figure 3. Aptamer Features
Figure 4. Other Features
Figure 5. Global Oligonucleotide Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Neuromuscular Diseases Case Studies
Figure 7. ATTR Case Studies
Figure 8. Hepatic VOD Case Studies
Figure 9. Other Case Studies
Figure 10. Oligonucleotide Therapeutics Report Years Considered
Figure 11. Global Oligonucleotide Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Oligonucleotide Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Oligonucleotide Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Oligonucleotide Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Oligonucleotide Therapeutics Market Share by Players in 2020
Figure 16. Global Top Oligonucleotide Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oligonucleotide Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Oligonucleotide Therapeutics Revenue in 2020
Figure 18. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Oligonucleotide Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Oligonucleotide Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Oligonucleotide Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Oligonucleotide Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Oligonucleotide Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Oligonucleotide Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Oligonucleotide Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Oligonucleotide Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Oligonucleotide Therapeutics Market Share by Region (2016-2027)
Figure 40. China Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Oligonucleotide Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Oligonucleotide Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Oligonucleotide Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Oligonucleotide Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Oligonucleotide Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Oligonucleotide Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Oligonucleotide Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Biogen Revenue Growth Rate in Oligonucleotide Therapeutics Business (2016-2021)
Figure 60. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2016-2021)
Figure 61. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2016-2021)
Figure 62. Bausch & Lomb Revenue Growth Rate in Oligonucleotide Therapeutics Business (2016-2021)
Figure 63. Alnylam Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2016-2021)
Figure 64. Dynavax Technologies Revenue Growth Rate in Oligonucleotide Therapeutics Business (2016-2021)
Figure 65. Kastle therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2016-2021)
Figure 66. Akcea Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed